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Summary
Cyclin D1 is overexpressed in the majority of human breast cancers. We previously found that mice lacking cyclin D1 are
resistant to mammary carcinomas triggered by the ErbB-2 oncogene. In this study, we investigated which function of cyclin
D1 is required for ErbB-2-driven mammary oncogenesis. We report that the ability of cyclin D1 to activate cyclin-dependent
kinase CDK4 underlies the critical role for cyclin D1 in breast cancer formation.We also found that the continued presence of
CDK4-associated kinase activity is required to maintain breast tumorigenesis. We analyzed primary human breast cancers
and found high cyclin D1 levels in a subset (w25%) of ErbB-2-overexpressing tumors. We propose that this subset of breast
cancer patients might benefit from inhibiting CDK4 kinase.Introduction
Cyclins represent key components of the core cell cycle machin-
ery. Two classes of cyclins are expressed during G1 phase pro-
gression in mammalian cells: D-type (cyclins D1, D2, and D3)
and E-type (cyclins E1 and E2). In contrast to other cyclins, which
are periodically induced during cell cycle progression, the levels
of D cyclins are controlled by extracellular mitogenic stimulation.
For this reason, D cyclins are regarded as links between the
cell environment and the core cell cycle machinery (Sherr and
Roberts, 1999).
Several different molecular functions have been ascribed
to the D-type cyclins. All three D cyclins were shown to bind
cyclin-dependent kinases CDK4 and CDK6 (Bates et al., 1994;
Matsushime et al., 1992; Meyerson and Harlow, 1994). The
resulting cyclin D-CDK complexes display two distinct func-
tions. In the ‘‘kinase-dependent’’ function, cyclin D-CDK4/6
complexes phosphorylate the retinoblastoma protein pRB, pRB-
related proteins p107 and p130, and Smad3 (Matsuura et al.,
2004; Sherr and Roberts, 1999). In addition to this ‘‘kinase-CANCER CELL 9, 23–32, JANUARY 2006 ª2006 ELSEVIER INC. DOI 10.dependent’’mechanism,cyclinD-CDKcomplexes titratep27Kip1
and p21Cip1 cell cycle inhibitors from cyclin E-CDK2 complexes
(which are inhibited by p27Kip1 and p21Cip1) to cyclin D-CDK,
thereby triggering the activity of the cyclin E-CDK2 holoenzyme
(Sherr and Roberts, 1999).
Moreover, D-type cyclins were shown to physically bind and
to activate or repress the activity of several transcription factors,
possibly through interacting with the associated transcriptional
regulators (Coqueret, 2002). Importantly, this function of the
D-type cyclins was shown to be independent of the binding to
CDKs (Coqueret, 2002). Lastly, D-type cyclins were shown to in-
teract with the components of the basal transcriptional machin-
ery (Adnane et al., 1999).
Consistent with their growth-promoting functions, overex-
pression of the D-type cyclins is seen in a large fraction of human
cancers. The cyclin D1 gene is rearranged or amplified in squa-
mous cell carcinomas of head and neck or esophagus; mantle
cell lymphomas; multiple myelomas; cancers of the lung, uterine
cervix, and stomach; and many other malignancies (Cheung
et al., 2001; Gao et al., 2004; Hoechtlen-Vollmar et al., 2000;S I G N I F I C A N C E
Overexpression of cyclin D1 is seen in all types of human breast cancers. In this study, we demonstrate that, in mice, the catalytic
activity of the cyclin D1-associated kinase CDK4 is critically required for mammary neoplasia driven by the ErbB-2 oncogene. In the
accompanying manuscript, Landis et al. demonstrate that knockin mice expressing kinase-deficient cyclin D1-CDK4 complexes
develop relatively normally, but they are resistant to mammary carcinomas triggered by ErbB-2. These results point to a differential
requirement for cyclin D1-CDK4 kinase activity inmammary neoplasia versus in development. These findings suggest that the pharma-
cological inhibition of CDK4 kinase might preferentially target breast cancer cells. Our findings will hopefully stimulate therapeutic
strategies aiming at blocking CDK4 kinase activity in cancer patients.1016/j.ccr.2005.12.012 23
A R T I C L ELammie et al., 1991; Reissmann et al., 1999; Vandenberghe,
1994). Of all these, the best documented is the frequent involve-
ment of cyclin D1 abnormalities in breast cancer.
Approximately 15%–20% of human breast cancers exhibit
amplification of the cyclin D1 gene (Buckley et al., 1993; Dickson
et al., 1995; Lammie et al., 1991), while the majority of human
mammary carcinomas overexpress cyclin D1 protein (Bartkova
et al., 1994, 1995; Gillett et al., 1994, 1996; McIntosh et al.,
1995). Overexpression of cyclin D1 is seen at the earliest stages
of breast cancer progression, such as ductal carcinoma in situ
(DCIS), but not in premalignant lesions, and it is maintained
at all stages of breast cancer progression, including metastatic
lesions (Bartkova et al., 1994; Gillett et al., 1996). These obser-
vations suggest that cyclin D1 might represent an attractive tar-
get for therapeutic intervention in mammary carcinomas.
We previously tested the requirement for cyclin D1 in normal
and in oncogenic proliferation by generating mice lacking cyclin
D1. These cyclin D1 null mice were viable and displayed very
narrow, circumscribed abnormalities, revealing that cyclin D1 is
dispensable for normal, nononcogenic proliferation of the vast
majority of cell types (Sicinski et al., 1995); similar conclusions
were independently reached by Fantl et al. (1995). We next
assessed the requirement for cyclin D1 in breast cancer forma-
tion by crossing cyclin D1 null mice with mouse mammary tumor
virus (MMTV)-oncogene transgenic mouse strains. Female mice
of these transgenic strains are highly prone to mammary carcino-
mas due to overexpression of particular oncogenes in their
mammary epithelium (Muller et al., 1988). Cyclin D1 null mice
were resistant to breast cancers driven by the ErbB-2 and Ras
oncogenes, while being fully susceptible to mammary carcino-
mas triggered by Wnt-1 and c-Myc (Yu et al., 2001). We con-
cluded that cyclin D1 function is critically required for ErbB-2-
and Ras-driven mammary gland tumorigenesis. However, these
studies did not reveal which function of cyclin D1 underlies its
critical importance in this process.
Among the many different cyclin D1 interactors listed above,
the CDK4 gene was found to be amplified and the protein over-
expressed in a significant fraction of human breast cancers (An
et al., 1999; Samady et al., 2004; Takano et al., 1999). We there-
fore hypothesized that the interaction of cyclin D1 with CDK4
might underlie the critical role for cyclin D1 in ErbB-2- and
Ras-driven breast tumorigenesis. We tested this hypothesis in
the studies described below.
Results
Normal development of CDK4 null mammary epithelium
To test the requirement for CDK4 function in breast cancer for-
mation, we used CDK4 null mice (Tsutsui et al., 1999). We first
analyzed mammary epithelial development in CDK4-deficient
females. Importantly, CDK42/2 females are infertile (Rane et al.,
1999; Tsutsui et al., 1999), and hence their pregnancy-driven
mammary lobuloalveolar development—the most extensive
step of mammary epithelial expansion—has not been previously
analyzed. We circumvented this developmental block by trans-
planting mammary epithelium from CDK4 null females into
cleared fat pads of wild-type recipients. Mammary epithelium
derived from wild-type littermates was transplanted into contra-
lateral fad pads of the same recipients and served as control.
When the recipient mice became pregnant, the CDK4 null epi-
thelium underwent extensive lobuloalveolar development that24was very similar to that seen in the wild-type counterpart (Fig-
ure 1A). These observations indicate that CDK4 is not required
for normal mammary epithelial development.
Normal appearance of CDK4 null mammary epithelium (Fig-
ure 1A), together with the profound defect seen in cyclin D1-
deficient mammary glands (Fantl et al., 1995, 1999; Sicinski
et al., 1995), raised the question of which function of cyclin D1
plays a role in driving mammary lobuloalveolar development.
Given earlier observations that ablation of p27Kip1 rescued the
phenotypic manifestations of cyclin D1 deficiency in mammary
glands (Geng et al., 2001; Tong and Pollard, 2001), we hypoth-
esized that the major function of cyclin D1 in mammary glands
Figure 1. Analyses of mammary glands in CDK4 null females
A:Normal mammary epithelial lobuloalveolar development inCDK42/2ani-
mals. Mammary epithelium was dissected from wild-type (WT) or CDK4
2/2
females and transplanted into wild-type recipients. The recipient mice
were mated, and the mammary glands were collected 1 day postpartum.
The mammary epithelium was stained with carmine red. Lower panels de-
pict higher magnification of the whole-mount images. Scale bars corre-
spond to 2 mm (upper panels) or 0.5 mm (lower panels).
B: Composition of cyclin D1-containing complexes. Cyclin D1 was immuno-
precipitated (IP Cyclin D1) from mammary glands of day 1 postpartum wild-
type mice (left panel) or from mammary glands of wild-type (WT) orCDK42/2
females that were hormonally stimulated to undergo lobuloalveolar devel-
opment (right panel) (see Experimental Procedures), and the immunoblots
were probed with the indicated antibodies. Straight lysates were immuno-
blotted and probed in parallel (Lysate). As a negative control, immunopre-
cipitation was performed in the absence of primary antibodies (Negative
control).CANCER CELL JANUARY 2006
A R T I C L Emay be mediated through sequestration of p27Kip1 by cyclin D1-
CDK complexes. We further hypothesized that, in the absence
of CDK4, other CDKs might form complexes with cyclin D1
and allow titration of p27Kip1. To address these possibilities,
we tested the composition of cyclin D1-containing complexes
in mammary glands of pregnant wild-type mice using immuno-
precipitation-Western blotting. We found that, in wild-type
glands, cyclin D1 associated with CDK4, CDK6, CDK2, and
p27Kip1 (Figure 1B). In CDK4 null mammary glands that were
stimulated by hormones to undergo lobuloalveolar develop-
ment, cyclin D1 associated with CDK6, CDK2, and p27Kip1
(Figure 1B). These results suggest that, in CDK4 null mammary
epithelium, cyclin D1 retains the ability to titrate p27 Kip1 through
its association with other CDKs.
Resistance of CDK42/2 mice to breast cancers
We and others previously showed that mice lacking cyclin D1
are resistant to mammary carcinomas triggered by the ErbB-2
oncogene (Yu et al., 2001; Bowe et al., 2002). In this study, we
asked whether cyclin D1’s catalytic partner, CDK4, is required
for ErbB-2-driven oncogenesis. To address this question, we
crossed CDK4 null mice with MMTV-ErbB-2 animals (Muller
et al., 1988), and we generated ErbB-2;CDK4+/+ and ErbB-2;
CDK42/2 females. The animals were then observed for tumor
occurrence. As expected, all CDK4+/+ females succumbed to
breast cancers and developed a total of 139 tumors. In contrast,
none of the CDK42/2 females developed mammary carcinomas
(Figures 2A and 2B). Upon termination of the experiment, the
mammary glands of ErbB-2;CDK42/2 mice were dissected and
extensively examined, and the absence of tumors was con-
firmed (data not shown). In addition, the hyperplastic changes,
seen in ErbB-2;CDK4+/+ mammary glands, were not encoun-
tered in CDK4 null counterparts (Figure 2C). Hence, genetic
ablation of CDK4, like ablation of cyclin D1, rendered mice resis-
tant to breast tumors triggered by ErbB-2. These results suggest
that the ability of cyclin D1 to interact with CDK4 may underlie
the critical requirement for cyclin D1 in ErbB-2-driven breast tu-
morigenesis.
To distinguish which of the two functions of cyclin D1-CDK4
complexes is required for ErbB-2-driven breast tumorigenesis,
together with Dr. Hinds’ group we generated a ‘‘knockin’’ strain
of mice expressing—in place of cyclin D1—a kinase-deficient
point mutant of cyclin D1 (see accompanying manuscript of
Landis et al., 2006). Importantly, this cyclin D1 mutant retains the
ability to bind CDK4 and to titrate p27Kip1, but it is unable to ac-
tivate CDK4 kinase. Knockin mice expressing kinase-deficient
cyclin D1-CDK4 complexes were resistant to breast cancers
driven by ErbB-2, like mice lacking cyclin D1 or CDK4. Collec-
tively, we interpret these results as an indication that cyclin
D1-CDK4 kinase activity is required for ErbB-2-driven breast
tumorigenesis.
Requirement for CDK4 function in tumor cell proliferation
The experiments described above addressed the requirement
for CDK4 kinase in the initiation of breast cancers. We next
asked whether the continued presence of CDK4 was required
to sustain tumor cell proliferation. We observed a very strong
upregulation of CDK4 and cyclin D1 in ErbB-2-driven tumors
(Figure 3A). Immunoprecipitation analyses revealed the pres-
ence of abundant cyclin D1-CDK4 complexes in ErbB-2-drivenCANCER CELL JANUARY 2006mammary carcinomas (Figures 3B and 3C); these tumors had
also elevated levels of CDK4- and cyclin D1-associated kinase
activity (Figure 3D and Figure S1 in the Supplemental Data
available with this article online). It should be noted, however,
that the increase in cyclin D1 and CDK4 protein levels (Figure 3A)
was much greater than the increase in CDK4- or cyclin D1-asso-
ciated kinase activity (Figure 3D and Figure S1). These observa-
tions are consistent with the notion that the tumor cells may rely
on cyclin D1-CDK4 complexes to drive tumor cell proliferation.
In order to rigorously test this possibility, we generated siRNA
against CDK4 that efficiently knocked down the levels of CDK4,
but not of CDK6 or CDK2 (Figure 4A and data not shown). We
isolated cells from mammary carcinomas arising in MMTV-
ErbB-2 mice and cultured tumor cells in vitro. We then infected
these cells with retroviruses encoding anti-CDK4 siRNA, or with
control vectors, and injected the cells into mammary fad pads of
recipient mice (Figure 4B). As expected, tumor cells infected
with control vectors rapidly formed mammary carcinomas in the
Figure 2. Resistance of CDK42/2 mice to ErbB-2-driven breast cancers
A: Percentage of tumor-free mice among MMTV-ErbB-2;CDK4+/+ and
MMTV-ErbB-2;CDK42/2 females.
B: The fraction of mice displaying mammary carcinomas at 40 weeks of age,
and the total number of tumors encountered in each group throughout the
entire observation period.
C: Histological appearance of hyperplastic mammary epithelial ducts en-
countered in wild-type (WT) but not inCDK42/2 females. Formalin-fixed, par-
affin-embedded sections were stained with hematoxylin and eosin. Scale
bars correspond to 100 mm.25
A R T I C L Erecipient mice (Figure 4C). In contrast, knockdown of CDK4
essentially blocked the ability of cells to form tumors (Figure 4C).
Consistent with these findings, analyses of in vitro cultured
tumor cells revealed that anti-CDK4 siRNA resulted in a de-
crease in the fraction of cells in the S phase (Figure S2),
further underscoring the requirement for CDK4 in tumor cell
proliferation.
Occasionally, we observed very small tumors arising from
cells infected with viruses encoding anti-CDK4 siRNA (Fig-
ure 4C). However, we found that these tumors expressed high
levels of CDK4 (Figure 4D), indicating that they arose from the
residual uninfected cells, or from cells that escaped knockdown
of CDK4. Collectively, these results suggest that CDK4 is criti-
cally required both for the initiation of tumors, and for mainte-
nance of tumor cell proliferation. We verified that this require-
ment was specific to CDK4, as knockdown of CDK6 using
Figure 3. Analyses of ErbB-2-driven mammary carcinomas
A: Western blot analysis of mammary glands derived from wild-type mice
(MG-WT), or mammary glands of MMTV-ErbB-2 mice (MG-ErbB2), or breast
tumors arising in MMTV-ErbB-2 mice (Tumor-ErbB2). Immunoblots were
probed with the indicated antibodies. Probing with antibodies against actin
was used to ensure equal loading.
BandC:Association of CDK4 with cyclin D1 in breast cancers. Cyclin D1 was
immunoprecipitated (D1-IP) (B), or CDK4 was immunoprecipitated (CDK4-
IP) (C) from mammary glands derived from wild-type mice (MG), or from
mammary tumors arising in MMTV-ErbB-2 mice (Tumor), or—for control—
from day 13.5 mouse embryos (Embryo), and the immunoblots were probed
with the indicated antibodies. Straight lysates were immunoblotted and
probed in parallel (Lysate).
D: Increased CDK4-associated kinase activity in breast tumors. CDK4 was im-
munoprecipitated from mammary glands derived from wild-type mice
(MG), or from breast cancers arising in MMTV-ErbB-2 mice (Tumor), and in vi-
tro kinase assay was performed using the recombinant retinoblastoma pro-
tein as a substrate.26a specific anti-CDK6 siRNA had little impact on the ability of cells
to form tumors (data not shown).
We also tested the requirement for CDK4’s regulatory partner,
cyclin D1, in tumor cell proliferation. We infected in vitro cultured
breast cancer cells with viruses encoding anti-cyclin D1 siRNA
(Figure 5A) and inoculated these cells into mammary fat pads.
As was the case with knockdown of CDK4, knockdown of cyclin
D1 blocked the ability of breast cancer cells to form tumors
(Figure 5B); similar results were reported by Lee et al. (2000) us-
ing antisense cyclin D1 in MMTV-neuT mammary tumor cell line.
We also verified that this requirement was specific to cyclin D1,
as knockdown of cyclin D3 using a specific, anti-cyclin D3
siRNA had only marginal impact on the ability of cells to form tu-
mors (data not shown). These observations suggest that cyclin
D1-CDK4 complexes are critically required to maintain tumor
cell proliferation.
Requirement for CDK4 kinase function in tumor cells
We next asked which function of cyclin D1-CDK4 complexes—
‘‘kinase-dependent’’ or ‘‘kinase-independent’’ was required to
drive the proliferation of breast cancer cells. As described above,
the resistance of knockin mice expressing kinase-deficient cy-
clin D1-CDK4 complexes to ErbB-2-driven breast tumors re-
vealed that the kinase function of cyclin D1-CDK4 was critically
required for the initiation of mammary carcinomas. To determine
which activity of cyclin D1-CDK4 complexes was needed to
maintain tumor cell proliferation, we replaced mouse CDK4 in
murine breast cancer cells with human wild-type CDK4 or with
human kinase-dead CDK4 (van den Heuvel and Harlow, 1993).
To this end, ErbB-2-driven breast cancer cells were infected
with retroviruses encoding anti-CDK4 siRNA, thereby efficiently
knocking down mouse CDK4 (Figure 6A). In the very same cells,
we retrovirally expressed human wild-type CDK4, or human
kinase-dead CDK4. Importantly, we designed our siRNA against
sequences that differ between mouse and human CDK4; there-
fore, the siRNA was specific for mouse CDK4 but would not af-
fect its human counterpart. The nearly complete knockdown of
mouse CDK4 and efficient expression of human CDK4 in tumor
cells was verified by the Western blotting (Figure 6A). We next in-
oculated these cells into mammary fat pads and observed the re-
cipient mice for tumor occurrence. As expected, reexpression of
human wild-type CDK4 endowed the cells with the ability to form
tumors; however, the tumor size was only 50% of that seen in
tumor cells infected with control vectors. In contrast, cells ex-
pressing kinase-dead CDK4 were unable to efficiently form tu-
mors (Figure 6B). Hence, the kinase activity of cyclin D1-CDK4
complexes is required both for the initiation of breast cancers
and to maintain tumor cell proliferation.
Analyses of human mammary carcinomas
Lastly, we asked whether the ErbB-2/cyclin D1 connection
might also operate in human breast cancers. We collected 22
primary mammary carcinomas containing amplification of the
ErbB-2 gene and examined the levels of cyclin D1 mRNA by mi-
croarray analysis. Twenty-three percent of these tumors (5/22)
contained high levels of cyclin D1 transcripts (Figure 7A).
It order to confirm these observations at a protein level, we
used an independent sample of 70 primary breast cancers with
ErbB-2 overexpression. Immunostaining of tumor sections with
anti-cyclin D1 antibodies revealed that 19/70 of tumors (27%)
contained very high levels of cyclin D1 protein (Figure 7B), whichCANCER CELL JANUARY 2006
A R T I C L EFigure 4. Knockdown of CDK4
A: Characterization of anti-CDK4 siRNA. Western
blot analyses of cells infected with retroviruses
encoding anti-CDK4 siRNA (anti-CDK4), or in-
fected with control retroviruses (Contr). Immuno-
blots were probed with an anti-CDK4 antibody,
and with an antibody against actin (to ensure
equal loading).
B: Experimental outline of the knockdown analy-
ses.
C: (Left) Appearance of tumors deriving from
breast cancer cells infected with control retrovi-
ruses (Contr), or infected with retroviruses encod-
ing anti-CDK4 siRNA (anti-CDK4). Control cells,
and cells that underwent CDK4 knockdown,
were inoculated into mammary glands of recip-
ient mice. After 3 weeks, mice were sacrificed
and all tumors were dissected. A representative
experiment is shown. (Right) Quantification of
the tumor weights. Error bars denote SD.
D: Small tumors that occasionally arise from cells
infected with viruses encoding anti-CDK4 siRNA
reexpress CDK4. Breast cancer cells were in-
fected with retroviruses encoding anti-CDK4
siRNA (anti-CDK4), or with control viruses (Contr).
Efficient knockdown of CDK4 in tumor cells was
verified by the Western blotting (Cells, CDK4).
Cells were injected into mammary fat pads,
and the recipient mice were observed for tumor
formation. Large tumors arising from cells in-
fected with control viruses, and small tumors
that occasionally arise from cells infected with
anti-CDK4 siRNA (see C) were dissected, and
the levels of CDK4 were determined by the West-
ern blotting (Tumors, CDK4). Note that the small
tumors expressed high levels of CDK4, indicating
that they arose from the residual uninfected
cells, or from cells that escaped the knockdown
of CDK4.exceeded the levels seen in the adjacent nontransformed tissue
(data not shown). Hence, a significant fraction of human ErbB-2-
overexpressing tumors contain elevated levels of cyclin D1. We
propose that the patients bearing this subset of mammary car-
cinomas might benefit from pharmacologically blocking CDK4
kinase activity.
Discussion
In the work described here, we report that—like cyclin D1 null
mice—animals lacking cyclin D1’s catalytic partner, CDK4, are
resistant to mammary carcinomas triggered by the ErbB-2 on-
cogene. We also found that the continued presence of CDK4
(and of cyclin D1) is critically required to maintain tumor cell
proliferation. While cyclin D1-CDK4 complexes have at least two
independent functions, we found that the catalytic, ‘‘kinase-
dependent’’ function of cyclin D1-CDK4 is needed to sustain
the tumorigenic potential of breast cancer cells.
In the accompanying manuscript, Landis et al. in collaboration
with us report generation and characterization of a knockin
strain of mice in which the wild-type copies of cyclin D1 were re-
placed by the cyclin D1 K112E ‘‘kinase-deficient’’ point mutant.
This mutant version of cyclin D1 can bind the CDKs, but it isCANCER CELL JANUARY 2006deficient in activating their kinase activities. Importantly, the mu-
tant protein retains the ability of cyclin D1-CDK complexes to
titrate cell cycle inhibitors p27Kip1 and p21Cip1. Analyses of the
homozygous knockin mice expressing kinase-deficient cyclin
D1-CDK complexes revealed relatively normal development of
cyclin D1-dependent compartments (retinas, mammary glands).
These analyses indicate that the kinase activity of cyclin D1-
CDK complexes is largely dispensable for development. It
seems likely that the major function of cyclin D1-CDK com-
plexes in development is to control cyclin E-CDK2 activation
through titration of p27Kip1 and p21Cip1. Indeed, ablation of
p27Kip1 in cyclin D1 null background restored nearly normal de-
velopment of cyclin D1 null mice (Geng et al., 2001; Tong and
Pollard, 2001), while ablation of p27Kip1 was shown to partially
correct the cell cycle abnormalities seen in CDK4 null cells
(Tsutsui et al., 1999). Consistent with this thinking, we observed
that titration of p27Kip1 by cyclin D1-containing complexes was
retained in CDK4 null mammary epithelium, likely explaining nor-
mal lobuloalveolar development in the absence of CDK4.
Strikingly, mice lacking cyclin D1, or CDK4, or mice express-
ing kinase-deficient cyclin D1-CDK complexes were resistant to
ErbB-2-driven mammary carcinomas. Collectively, these results
point to a differential requirement for cyclin D1-CDK4 kinase27
A R T I C L Eactivity in mammary neoplasia versus normal mammary devel-
opment.
Why are breast cancer cells critically dependent on cyclin D1-
CDK4 kinase for their proliferation? The expression pattern of
the D cyclins and CDKs seen in ErbB-2-driven tumors (Figure 3)
may provide a partial answer. We found that these tumor cells
express mostly cyclin D1 (but little D2 or D3) and predominantly
CDK4. These findings likely explain why knockdown of cyclin
D3 or CDK6 has very little impact on tumor cell proliferation.
However, it remains unclear why the kinase activity of cyclin
D1-CDK4 complexes plays such a critical function in tumor
cells, but not in developing tissues. One possibility is that, in tu-
mor cells, phosphorylation of the retinoblastoma protein by cy-
clin D-CDK4 kinase must take place in order to upregulate cyclin
E levels (via E2Fs) and to activate cyclin E-CDK complexes. In
contrast, in nontransformed cells the noncatalytic function of cy-
clin D-CDK complexes may suffice to activate cyclin E-associ-
ated kinase activity through titration of inhibitors. Alternatively,
tumor cells may express a protein (or proteins) that represents
a specific target of cyclin D1-CDK4 kinase. However, this re-
quirement for cyclin D1-CDK4 kinase cannot be absolute, as
evidenced by our observations that knockin mice expressing
cyclin E1 in place of cyclin D1 remained susceptible to ErbB-
2-driven breast cancers (Yu et al., 2001). Hence, elevated and/
or sustained levels of cyclin E may obviate the requirement for
cyclin D1-CDK4 kinase. Indeed, Bowe et al. (2002) have re-
ported that a small fraction of MMTV-ErbB-2;cyclin D12/2
mice developed mammary carcinomas after very long latency,
and that these mammary tumors markedly upregulate cyclin E
levels.
Regardless of these questions, our results may have poten-
tially important implications for breast cancers in humans. For
this reason, in the current study we extended our analyses to
Figure 5. Knockdown of cyclin D1
A: Characterization of anti-cyclin D1 siRNA. Western blot analyses of cells in-
fected with retroviruses encoding anti-cyclin D1 siRNA (anti-D1), or infected
with control retroviruses (Contr). Immunoblots were probed with an anti-
cyclin D1 antibody, and with an antibody against actin (to ensure equal
loading).
B: (Left) Appearance of tumors deriving from cells infected with control ret-
roviruses (Contr), or infected with retroviruses encoding anti-cyclin D1 siRNA
(anti-D1). Control cells, and cells that underwent cyclin D1 knockdown,
were inoculated into mammary glands of recipient mice. After 3 weeks,
mice were sacrificed and all tumors were dissected. A representative exper-
iment is shown. (Right) Quantification of the tumor weights. Error bars de-
note SD.28human mammary carcinomas. It is very well documented that
the majority of human breast cancers overexpress cyclin D1
(Barnes and Gillett, 1998; Musgrove et al., 1996; Zhou et al.,
2001), and that up to 40% of mammary carcinomas exhibit am-
plification and/or overexpression of the ErbB-2 gene (Andrulis
et al., 1998; Bieche and Lidereau, 1995; Slamon et al., 1987).
However, it is less clear whether there is any overlap between
these two groups. In the current study, we analyzed nearly
100 primary human breast cancer specimens with confirmed
ErbB-2 overexpression. We found that approximately 25% of
them contained elevated cyclin D1 levels. This is in contrast to
MMTV-ErbB-2 transgenic mice, where high cyclin D1 levels
are seen in essentially all tumors (Figure 3). We presume that
MMTV-ErbB-2 transgenic mice, used in our study, model this
Figure 6. Replacement of mouse CDK4 with human wild-type or kinase-
dead CDK4
A: Breast cancer cells were infected with control viruses (Contr), or with
viruses encoding anti-mouse CDK4 siRNA (anti-CDK4), or with viruses encod-
ing anti-mouse CDK4 siRNA plus human wild-type CDK4 (anti-CDK4 + WT
CDK4), or anti-mouse CDK4 siRNA plus human kinase-dead CDK4 (anti-
CDK4 + kinase-dead CDK4). Protein lysates were probed with an antibody
recognizing mouse CDK4 (left panel) or human CDK4 (right panel). Note
that the anti-human CDK4 antibody also cross-reacts with mouse CDK4
(the cross-reacting band is marked by an asterisk). The blots were also
probed with antibodies against actin, to ensure equal loading.
B: Quantification of the tumor weights. Tumor cells were infected with con-
trol viruses (Contr), or with viruses encoding anti-mouse CDK4 siRNA (anti-
CDK4), or anti-mouse CDK4 siRNA plus human wild-type CDK4 (anti-CDK4 +
WT CDK4), or anti-mouse CDK4 siRNA plus human kinase-dead CDK4 (anti-
CDK4 + kinase dead CDK4). Cells were then inoculated into mammary fat
pads of the recipient mice. Mice were sacrificed after 3 weeks, and tumors
were dissected and weighed. A representative experiment is shown. Error
bars denote SD.CANCER CELL JANUARY 2006
A R T I C L EFigure 7. Expression of cyclin D1 in human ErbB-2-
positive mammary carcinomas
A: RNA was extracted from pretreatment core
biopsy specimens of 22 mammary carcinomas
with ErbB-2 gene amplification (as determined
by FISH), and with ErbB-2 overexpression (‘‘+++’’
according to DAKO Herceptest) and hybridized
onto Affymetrix Gene Chip. Unsupervised hierar-
chical clustering was performed using the cyclin
D1 probe set. Fold expression of cyclin D1 above
and below the mean is depicted below in the
red-blue dendrogram. Also shown is the clinical
stage of the tumor (AJCC T-stage, 2 to 4) and
the estrogen receptor (ER) or progesterone re-
ceptor (PR) status (P = positive, N = negative),
measured by immunocytochemistry.
B: 238 human primary breast cancer specimens
(70 cases of ErbB-2-positive, 168 cases of ErbB-2-
negative) were stained with anti-cyclin D1 anti-
bodies and classified into cyclin D1-low, -inter-
mediate, and -high. Among 70 ErbB-2-positive
tumors, 19 (27%) scored as cyclin D1 high. An ex-
ample of an ErbB-2-positive/cyclin D1-high tu-
mor is shown. Sections were stained for cyclin
D1 or ErbB-2, or with control antibodies. Scale
bars correspond to 100 mm.subset of ErbB-2-positive/cyclin D1-overexpressing human
mammary carcinomas.
Importantly, patients bearing ErbB-2-positive, cyclin D1-over-
expressing tumors have shown particularly poor prognosis, with
only 13% of women surviving 7 years (Ahnstro¨m et al., 2005). In
contrast, patients with ErbB-2-positive/cyclin D1-negative
tumors had survival rates of nearly 50% over the same period
(Ahnstro¨m et al., 2005). Hence, among ErbB-2-positive breast
cancers, overexpression of cyclin D1 confers particularly unfa-
vorable prognosis. We propose that the patients bearing this
type of breast cancer might benefit from pharmacologically
blocking CDK4 kinase activity. We further propose that this ther-
apy might selectively target breast cancer cells, while sparing
other tissues where cyclin D1-CDK4 kinase activity seems not
to be essential for the normal, nononcogenic proliferation.
The work described in this manuscript focused on mammary
carcinomas. However, amplification of the ErbB-2 gene and
overexpression of ErbB-2 protein were reported in several hu-
man malignancies including ovarian cancers, pancreatic adeno-
carcinomas, non-small cell lung cancers, biliary tract cancers,
invasive bladder cancers, squamous cell carcinoma of the
esophagus, gastric cancers, uterine serous papillary carcino-
mas, and many others (Berchuck et al., 1990; Eltze et al., 2005;
Hansel et al., 2005; Mimura et al., 2005; Nakazawa et al., 2005;
Santin et al., 2005; Tanner et al., 2005; Ugocsai et al., 2005). In
addition, mutational activation of ErbB-2 was documented in
10% of lung adenocarcinomas (Stephens et al., 2004). Some
of these tumor types were also shown to contain elevated levels
of cyclin D1 and CDK4 (Cheung et al., 2001; Dong et al., 2001;
Igarashi et al., 1999; Masaki et al., 2003). We hypothesize thatCANCER CELL JANUARY 2006these tumors might also benefit from pharmacological inhibition
of the CDK4 kinase. Our findings will hopefully stimulate thera-




Generation of CDK4-deficient mice was described previously (Tsutsui et al.,
1999). MMTV-ErbB-2 mice (strain TG.NK; Muller et al., 1988) were purchased
from the Charles River Laboratories. Mating of the two strains yielded the
two experimental groups: MMTV-ErbB-2;CDK4+/+ (n = 42) and MMTV-
ErbB-2;CDK42/2 (n = 38 at 40 weeks, n = 18 at 51 weeks, n = 13 at 55 weeks;
CDK42/2mice show reduced life spans due to diabetes [Tsutsui et al., 1999]).
Mice were kept as virgins and were checked biweekly, by palpation, for tu-
mor occurrence. Animals displaying tumors were sacrificed, and the pres-
ence of mammary adenocarcinomas was confirmed histologically. Animals
were observed for a total of 55–60 weeks. At the end of the observation
period, mammary glands were dissected from all tumor-free mice (100%
of MMTV-ErbB-2;CDK42/2, none from the MMTV-ErbB-2;CDK4+/+ group)
and extensively analyzed for the presence of tumors. All experiments were
approved by the Animal Care and Use Committee at the Dana-Farber Cancer
Institute and were performed in accordance with relevant institutional and
national guidelines and regulations.
Mammary gland analyses
Mammary epithelial transplantations and whole-mount analyses were per-
formed essentially as described (Geng et al., 1999, 2001). Six CDK42/2
and six wild-type female littermates (4 months old) served as donors. Mam-
mary epithelium from each donor mouse was transplanted into at least five to
six recipient females. Mice were mated 2 months after the transplantation.
For analyses of cyclin D1-containing complexes (Figure 1B), wild-type (n = 6)
or CDK42/2 (n = 7) females were implanted with a pellet containing 0.5 mg29
A R T I C L Eof 17b-estradiol plus 32.5 mg of progesterone (HH-114, Innovative Research
of America) for 21 days, and with a pellet (X-999, Innovative Research of
America) containing 3.5 mg of prolactin from sheep pituitary (Sigma, L6520)
for 14 days. The mammary glands were then collected and processed for im-
munoprecipitations.
Western blotting, immunoprecipitation, and kinase assays
Protein lysates (25–50 mg) were resolved using 10% PAGE, transferred to
Immobilon-P filters (Millipore), and probed with antibodies against the follow-
ing proteins: cyclin D1 (Ab-3, Neomarkers), cyclin D2 (M-20, Santa Cruz), cy-
clin D3 (C-16, Santa Cruz), mouse CDK4 (Ab-5, Neomarkers), human CDK4
(C-22, Santa Cruz), CDK6 (C-21, Santa Cruz), CDK2 (M-2, Santa Cruz),
p27Kip1 (C-19, Santa Cruz), or actin (MAB1501, Chemicon). For immunopre-
cipitation, 200 mg of protein lysates were immunoprecipitated with anti-CDK4
(Ab-1, Neomarkers) or anti-cyclin D1 (72-13G, Santa Cruz) antibodies, re-
solved on 10% PAGE, and transferred to Immobilon-P filters (Millipore).
For in vitro kinase reactions, 200 mg of protein lysates were immunoprecipi-
tated with antibodies against CDK4 (C-22AC, Santa Cruz), cyclin D1 (17-13G,
Santa Cruz), or CDK2 (M-2, Santa Cruz). Immunoprecipitates were incubated
with the C-terminal fragment of the retinoblastoma protein (Santa Cruz) or
histone H1 protein (Roche) in the presence of g32P-ATP as described
(Geng et al., 2001). Labeled proteins were resolved using 10% PAGE and
visualized by autoradiography.
siRNA experiments
Mammary carcinomas were dissected from MMTV-ErbB-2 females; the cells
were digested with 0.25% trypsin, plated, and cultured in DMEM and 10%
fetal bovine serum. Two immortalized cell lines, designated V720 and A249,
were derived and used for subsequent experiments, along with the SMF cell
line, which was also derived from MMTV-ErbB-2 mammary carcinoma and
was kindly provided by Dr. Philip Leder. siRNA sequences against mouse
CDK4 (50-AACATTCTAGTGACAAGTAAT-30) or mouse cyclin D1 (50-CCACA
GATGTGAAGTTCATTT-30) were cloned into pMKO.1 (Sicinska et al., 2003)
retroviral vectors. For control, we used empty pMKO.1 retroviruses or
pMKO.1 viruses encoding anti-GFP siRNA (50-GGCTACGTCCAGGAGCG
CACC-30) (kindly provided by Drs. William Hahn and Richard Possemato),
anti-mouse CDK6 siRNA (kindly provided by Dr. Phillip W. Hinds), or anti-
mouse cyclin D3 siRNA (50-ATGTATCCTCCATCCATGATC-30). Tumor cells
were infected with pMKO.1 retroviruses and selected with puromycin
(6 mg/ml) for 2–6 days. For replacement of mouse CDK4 with human
CDK4, tumor cells were first infected with pLXSN-based retroviruses encod-
ing wild-type human CDK4, or with retroviruses encoding kinase-dead hu-
man CDK4 (CDK4N158) containing Asp-to-Asn substitution at amino acid res-
idue 158 (van den Heuvel and Harlow, 1993), or with empty pLXSN vectors,
and the cells were selected with 1200 mg/ml of neomycin for 2 days. Subse-
quently, cells were infected with pMKO.1 vectors encoding anti-mouse
CDK4 siRNA and selected in puromycin as above.
Tumor cells (106) were injected into mammary fat pads of 3- to 4-month-old
Rag 12/2 females (purchased from the Jackson Labs). Mice were monitored
by palpation every other day for the presence of tumors. After 3 weeks, mice
were sacrificed and tumors were dissected. In each experiment, particular
cells were injected into three to five recipient females (six to ten injection
sites), and the experiment was repeated at least three times.
Analyses of human breast cancers
For RNA analyses, nucleic acids were extracted from frozen tissue core biop-
sies of 22 mammary carcinomas using Qiagen nanoprep kit and subjected to
two rounds of in vitro transcription; the second round incorporated biotiny-
lated NTPs for labeling. RNA was then hybridized to Affymetrix U113 plus
2.0 Gene Arrays.
For immunocytochemistry, tumors consisted of a subset of 70 ErbB-2-
positive breast cancers originating from two previous studies (Ahnstro¨m
et al., 2005; Sta˚l et al., 2000). The patients were postmenopausal women
with the diagnosis of stage II breast cancer (UICC). The ErbB-2 status was
assessed by flow cytometry, and 70/238 tumors scored positive. Freshly
cut frozen sections were stained for cyclin D1 using a rabbit polyclonal anti-
body (Neomarkers), followed by a secondary Multilink swine anti-goat/
mouse/rabbit antibody conjugated to biotin (Dako, Denmark) and streptavi-
din-horseradish peroxidase. The immunoreactivity was visualized with 3,3-
diaminobenzidine hydrochloride (DAB), and the cells were counterstained30with hematoxylin. The intensity of cyclin D1 immunostaining was graded as
weak, moderate, or strong. For ErbB-2 immunostaining shown in Figure 7B,
monoclonal antibody (Ab-2, Oncogene Science) was used, followed by
peroxidase-conjugated EnVision complexes (Dako, Denmark) and visuali-
zation with DAB. Cells were counterstained with hematoxylin.
Supplemental data
The Supplemental Data include two supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/1/23/
DC1/.
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